References
- Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37 (8): 997–1005.
- Postier R, Klein S, Green S, Loh E. Results of a phase 2, open-label, safety, and efficacy study of tigecycline to treat complicated skin and skin structure infections in hospitalized patients. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 2003; 43: 416.
- Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35 (4): 381–389.
- Siami FS, LaFleur BJ, Siami GA. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther 2002; 24 (1): 59–72.
- Breedt J, Teras J, Gardovskis J, et al. The safety and efficacy of tigecycline in the treatment of skin and skin struc-ture infections: results of a double-blind phase 3 comparison study with vancomycin/aztreonam. Antimicrob Agents Chemother 2005: in press.
- Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, dou-ble-blind trial. Int J Infect Dis 2005 in press.
- Mallick R, Solomon S. Risk factors for prolonged hospi-talization in treatment of complicated skin infections: evidence from a randomized clinical trial comparing tigecycline with vancomycin/aztreonam. In: American College of Clinical Pharmacy 2005 Spring Forum; 2005 April 10-13, 2005; San Francisco; 2005.
- Murray J, Wilson S, Klein S, Yellin A, Loh E. The clini-cal response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2 clinical trial. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 2003; 43: 416.
- Dartois N, Gioud-Paquet M, Ellis-Grosse EJ, Loh E. Tigecycline vs imipenem/cilastatin for treatment of complicat-ed intra-abdominal infections. In: ICAAC 2004; 2004; October 30-November 2, 2004, Washington DC; 2004.
- Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilas-tatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005 in press.
- Poster RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E, Tigecycline-200 Study Group. Results of a multicenter, ran-domized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26 (5): 704–714.